Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Zevra Therapeutics Inc. (ZVRA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: ZVRA (4-star) is a SELL. SELL since 1 days. Profits (9.34%). Updated daily EoD!
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $23.22
1 Year Target Price $23.22
| 4 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 32.34% | Avg. Invested days 44 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 519.44M USD | Price to earnings Ratio - | 1Y Target Price 23.22 |
Price to earnings Ratio - | 1Y Target Price 23.22 | ||
Volume (30-day avg) 7 | Beta 1.87 | 52 Weeks Range 6.19 - 13.16 | Updated Date 08/14/2025 |
52 Weeks Range 6.19 - 13.16 | Updated Date 08/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.25 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-08-19 | When - | Estimate 2.19 | Actual -0.06 |
Profitability
Profit Margin 4.26% | Operating Margin (TTM) -47.64% |
Management Effectiveness
Return on Assets (TTM) -18.85% | Return on Equity (TTM) 3.53% |
Valuation
Trailing PE - | Forward PE 17.48 | Enterprise Value 379109043 | Price to Sales(TTM) 8.38 |
Enterprise Value 379109043 | Price to Sales(TTM) 8.38 | ||
Enterprise Value to Revenue 6.11 | Enterprise Value to EBITDA 10.4 | Shares Outstanding 54679600 | Shares Floating 47234311 |
Shares Outstanding 54679600 | Shares Floating 47234311 | ||
Percent Insiders 0.69 | Percent Institutions 62.1 |
Upturn AI SWOT
Zevra Therapeutics Inc.
Company Overview
History and Background
Zevra Therapeutics, formerly KemPharm, was founded in 2006. The company initially focused on prodrugs and has evolved to focus on rare diseases. They have rebranded to reflect their shift in focus.
Core Business Areas
- Rare Disease Therapeutics: Focuses on developing and commercializing therapies for rare diseases, including those affecting the central nervous system.
Leadership and Structure
Richard A. Pascoe serves as the Chief Executive Officer. The company has a typical organizational structure for a publicly traded pharmaceutical company, with various departments focused on research and development, commercialization, and administration.
Top Products and Market Share
Key Offerings
- OLPRUVA (sodium phenylbutyrate): Indicated for use as a nitrogen-binding agent for long-term management of urea cycle disorders (UCDs). Market share is difficult to ascertain precisely, but Zevra is actively competing with established therapies. Competitors include Horizon Therapeutics (Ravicti, Buphenyl).
- KEMDYSA (methylphenidate hydrochloride) Chewable Tablets: KEMDYSA is a treatment for attention deficit hyperactivity disorder (ADHD) in patients 6 years and older. It is sold by another company under agreement. Competitors include other ADHD medications like Adderall, Concerta, and Ritalin.
Market Dynamics
Industry Overview
The rare disease therapeutics market is growing rapidly, driven by increased awareness, orphan drug designations, and advancements in genetic research. This sector faces challenges such as high development costs and complex regulatory pathways.
Positioning
Zevra is positioning itself as a player in the rare disease space, focusing on areas with unmet medical needs. Their competitive advantage lies in their ability to acquire and develop therapies for niche markets.
Total Addressable Market (TAM)
The global rare disease market is projected to reach hundreds of billions of dollars. Zevra is positioned to capture a share of this TAM by focusing on specific rare diseases and developing targeted therapies.
Upturn SWOT Analysis
Strengths
- Focus on rare diseases
- Experienced management team
- Established commercial infrastructure
- Growing revenue
Weaknesses
- Limited product pipeline
- Dependence on key products
- Small market capitalization
- Potential for regulatory setbacks
Opportunities
- Expansion into new rare disease areas
- Acquisition of additional product candidates
- Strategic partnerships
- Potential for orphan drug designations
Threats
- Competition from larger pharmaceutical companies
- Generic erosion of key products
- Changes in regulatory landscape
- Economic downturn
Competitors and Market Share
Key Competitors
- Horizon Therapeutics (HZNP)
Competitive Landscape
Zevra is a smaller player compared to larger pharmaceutical companies. Their competitive advantage lies in focusing on niche rare disease markets.
Major Acquisitions
Azevan Pharmaceuticals, Inc.
- Year: 2023
- Acquisition Price (USD millions): 15
- Strategic Rationale: The acquisition of Azevan Pharmaceuticals, Inc. added arimoclomol, a Phase 2b asset with orphan drug and rare pediatric disease designations, being developed for Niemann-Pick disease type C (NPC), to Zevrau2019s development pipeline.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends would need to be extracted from Zevra's financial statements over the past several years.
Future Projections: Future projections are typically based on analyst estimates and company guidance. These estimates can be found on financial websites.
Recent Initiatives: Recent initiatives include the acquisition of new product candidates and efforts to expand commercial reach.
Summary
Zevra Therapeutics is a growing pharmaceutical company focused on rare diseases. Its revenue streams and key products show promise. The small market cap presents challenges as they compete with larger companies with deeper pockets. Continued pipeline development and strategic acquisitions are critical for sustained growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Investor Relations Website
- Third-Party Financial Data Providers
- Industry News and Reports
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Market share estimates are approximate and subject to change. Actual results may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Zevra Therapeutics Inc.
Exchange NASDAQ | Headquaters Celebration, FL, United States | ||
IPO Launch date 2015-04-16 | President, CEO & Director Mr. Neil F. McFarlane | ||
Sector Healthcare | Industry Biotechnology | Full time employees 59 | Website https://zevra.com |
Full time employees 59 | Website https://zevra.com | ||
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 1/2 clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit and hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and MIPLYFFA for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.